Quinn Dinh

Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis

James F. Chmiel, Patrick A. Flume, D.G. Downey et al. · Journal of Cystic Fibrosis · 2020 · 68 citations · Full text

Medicine, Placebo-controlled Trial, Clinical Trials +1

Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials

Deborah Elstein, Björn Mellgård, Quinn Dinh et al. · Molecular Genetics and Metabolism · 2017 · 49 citations · Full text

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

Robert Spiera, Masataka Kuwana, Dinesh Khanna et al. · Arthritis & Rheumatology · 2023 · 40 citations · Full text

Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials

Ari Zimran, Deborah Elstein, Derlis Gonzalez et al. · Blood Cells Molecules and Diseases · 2016 · 29 citations · Full text

Enzyme Replacement Therapy, Substrate Reduction Therapy, Osteoporosis +16

A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale

Robert Spiera, Dinesh Khanna, Masataka Kuwana et al. · Clinical and Experimental Rheumatology · 2021 · 18 citations · Full text